Clinical trial
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV…
NCT00003562 · Hope Cancer Institute, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00003562 |
|---|---|
| Title | Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
| Official title | A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin |
| Lead sponsor | Hope Cancer Institute, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, docetaxel |
| Enrollment | 38 |
| Start date | Jul 1, 1998 |
| First posted | May 21, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: